A systematic review and meta-analysis, published in 2012, identified 116 reports from 65 trials of antipsychotic therapy in patients with schizophrenia.[Leucht et al., 2012] This information amounted to data for 6,493 patients.[Leucht et al., 2012] The results demonstrated that maintenance antipsychotic therapy has benefits for patients, including reduced risk of relapse, improved quality of life, and reduced aggressive acts.[Leucht et al., 2012] However, the authors caution that the benefits of antipsychotic treatment must be weighed against the risk of adverse events.[Leucht et al., 2012]
Reference:
Leucht S, Tardy M, Komossa K, et al. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet 2012; 379 (9831): 2063–2071.
Other references used on slide:
Kishimoto T, Hagi K, Nitta M, et al. Effectiveness of long-acting injectable vs oral antipsychotics in patients with schizophrenia: a meta-analysis of prospective and retrospective cohort studies. Schizophr Bull 2018; 44 (3): 603–619.
Kishimoto T, Nitta M, Borenstein M, et al. Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013; 74 (10): 957–965.